Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
This site is intended for healthcare professionals

Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT

November 11, 2023

3

Final results of the SELECT trial have shown that the anti-obesity drug semaglutide (Wegovy) produced a consistent reduction of around 20% vs placebo across major cardiovascular event endpoints over the approximately 3-year follow-up in patients with overweight or obesity and cardiovascular disease but not diabetes.

"This is a very exciting set of results. I think it is going to have a big impact on a large number of people," lead investigator A. Michael Lincoff, MD, vice chair for research in the department of cardiovascular medicine at the Cleveland Clinic, Cleveland, Ohio, told theheart.org | Medscape Cardiology. 

"And from a scientific standpoint, these data show that we now have a new pathway or a new modifiable risk factor for cardiovascular disease that we can use in our patients who have overweight or obesity," he added.

The trial involved 17,604 patients with a history of cardiovascular disease and a BMI of 27 or above (mean BMI was 33), who were randomly assigned to the glucagon-like peptide 1 (GLP-1) agonist semaglutide, given by subcutaneous injection once weekly at a gradually escalating dose up to 2.4 mg daily by week 16, or placebo. The mean baseline glycated hemoglobin level was 5.8% and 66.4% of patients met the criteria for prediabetes.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....